Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 22Terminated 9Unknown 2Recruiting 2Not yet recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Gastrointestinal 1

Conditions

Thromboembolism 1Stomach Neoplasms 1Pancreatic Neoplasms 1Lung Neoplasms 1Gastrointestinal Stromal Tumors 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Duodenal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Biliary Tract Neoplasms 1

Interventions

Cisplatin 517Radiotherapy 378Cyclophosphamide 368Carboplatin 359Capecitabine 342Paclitaxel 337Oxaliplatin 336Gemcitabine 322Docetaxel 317Fluorouracil 290Drug Therapy 276Bevacizumab 248apatinib 247camrelizumab 219Etoposide 201Irinotecan 182Doxorubicin 181Leucovorin 163Dexamethasone 161pembrolizumab 153Neoadjuvant Therapy 146sintilimab 145anlotinib 140Blood Specimen Collection 140Pemetrexed 138Cytarabine 138toripalimab 133Surgical Procedures, Operative 131Radiosurgery 131S 1 (combination) 125

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Dalteparin × Clear all
NCT03139487 2020-01-06

PRIORITY

Asan Medical Center

Phase 2 Unknown
176 enrolled
GastrointestinalSarcoma

Biliary Tract Neoplasms, Duodenal Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Stomach Neoplasms, Cholangiocarcinoma, Gastrointestinal Stromal Tumors

NCT00519805 2011-08-08

Dalteparin in Preventing Blood Clots in Patients With Lung Cancer

National Cancer Institute (NCI)

Phase 3 Unknown
2,200 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡